Anthony Rothschild to Depression
This is a "connection" page, showing publications Anthony Rothschild has written about Depression.
Connection Strength
2.051
-
Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013 Oct; 74(10):966-73.
Score: 0.268
-
Yuan Y, Barooah A, Lapane KL, Mack D, Rothschild AJ, Ulbricht CM. Health Profile Transitions and the Association With Cognitive Impairment in Older Nursing Home Residents With Suicidal Ideation. Int J Geriatr Psychiatry. 2024 10; 39(10):e70003.
Score: 0.143
-
Rothschild AJ. Maintenance treatment of psychotic depression: Is antipsychotic medication needed? Acta Psychiatr Scand. 2024 01; 149(1):3-5.
Score: 0.136
-
Tani H, Moxon-Emre I, Forde NJ, Neufeld NH, Bingham KS, Whyte EM, Meyers BS, Alexopoulos GS, Hoptman MJ, Rothschild AJ, Uchida H, Flint AJ, Mulsant BH, Voineskos AN. Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication. Brain Imaging Behav. 2024 Feb; 18(1):117-129.
Score: 0.135
-
Rothschild AJ. Should Antipsychotic Medications Be Prescribed to Patients With Nonpsychotic Depression? J Clin Psychopharmacol. 2022 May-Jun 01; 42(3):231-233.
Score: 0.121
-
Patel DA, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS, Mulsant BH, Voineskos AN, Marino P, Alexopoulos GS. Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. J Clin Psychopharmacol. 2021 Mar-Apr 01; 41(2):196-199.
Score: 0.112
-
Yuan Y, Lapane KL, Rothschild AJ, Ulbricht CM. Changes in depressive symptoms and cognitive impairment in older long-stay nursing home residents in the USA: a latent transition analysis. Aging Ment Health. 2021 10; 25(10):1903-1912.
Score: 0.110
-
Yuan Y, Min HS, Lapane KL, Rothschild AJ, Ulbricht CM. Depression symptoms and cognitive impairment in older nursing home residents in the USA: A latent class analysis. Int J Geriatr Psychiatry. 2020 07; 35(7):769-778.
Score: 0.105
-
Neufeld NH, Mulsant BH, Dickie EW, Meyers BS, Alexopoulos GS, Rothschild AJ, Whyte EM, Hoptman MJ, Nazeri A, Downar J, Flint AJ, Voineskos AN. Resting state functional connectivity in patients with remitted psychotic depression: A multi-centre STOP-PD study. EBioMedicine. 2018 Oct; 36:446-453.
Score: 0.095
-
Silver M, Moore CM, Villamarin V, Jaitly N, Hall JE, Rothschild AJ, Deligiannidis KM. White matter integrity in medication-free women with peripartum depression: a tract-based spatial statistics study. Neuropsychopharmacology. 2018 06; 43(7):1573-1580.
Score: 0.090
-
Ulbricht CM, Rothschild AJ, Hunnicutt JN, Lapane KL. Depression and cognitive impairment among newly admitted nursing home residents in the USA. Int J Geriatr Psychiatry. 2017 Nov; 32(11):1172-1181.
Score: 0.086
-
Ulbricht CM, Rothschild AJ, Lapane KL. Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. J Womens Health (Larchmt). 2016 05; 25(5):464-72.
Score: 0.077
-
Ulbricht CM, Rothschild AJ, Lapane KL. The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. J Affect Disord. 2015 Dec 01; 188:270-7.
Score: 0.076
-
Bodenlos JS, Schneider KL, Oleski J, Gordon K, Rothschild AJ, Pagoto SL. Vagus nerve stimulation and food intake: effect of body mass index. J Diabetes Sci Technol. 2014 May; 8(3):590-5.
Score: 0.069
-
Smith E, Rothschild AJ, Heo M, Peasley-Miklus C, Caswell M, Papademetriou E, Flint AJ, Mulsant BH, Meyers BS. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int Clin Psychopharmacol. 2008 May; 23(3):130-7.
Score: 0.046
-
Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
Score: 0.044
-
Sit D, Rothschild AJ, Creinin MD, Hanusa BH, Wisner KL. Psychiatric outcomes following medical and surgical abortion. Hum Reprod. 2007 Mar; 22(3):878-84.
Score: 0.042
-
Banerjee S, Wu Y, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Oliver LD, Power JD, Rothschild AJ, Sirey JA, Voineskos AN, Whyte EM, Alexopoulos GS, Flint AJ. Trajectories of remitted psychotic depression: identification of predictors of worsening by machine learning. Psychol Med. 2024 Apr; 54(6):1142-1151.
Score: 0.034
-
Bingham KS, Calarco N, Dickie EW, Alexopoulos GS, Butters MA, Meyers BS, Marino P, Neufeld NH, Rothschild AJ, Whyte EM, Mulsant BH, Flint AJ, Voineskos AN. The relationship of white matter microstructure with psychomotor disturbance and relapse in remitted psychotic depression. J Affect Disord. 2023 08 01; 334:317-324.
Score: 0.033
-
Men X, Marshe V, Elsheikh SS, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Rothschild AJ, Voineskos AN, Whyte EM, Kennedy JL, Flint AJ, M?ller DJ. Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study. Neuropsychobiology. 2023; 82(3):168-178.
Score: 0.032
-
Song J, Mulsant BH, Sanches M, Alexopoulos GS, Marino P, Meyers BS, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Gerretsen P. Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study. J Affect Disord. 2023 03 15; 325:29-34.
Score: 0.032
-
Flint AJ, Bingham KS, Alexopoulos GS, Marino P, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Meyers BS. Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial. J Psychiatr Res. 2023 01; 157:285-290.
Score: 0.032
-
Bingham KS, Neufeld NH, Alexopoulos GS, Marino P, Mulsant BH, Rothschild AJ, Voineskos AN, Whyte EM, Meyers BS, Flint AJ. Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study. Psychiatry Res. 2022 08; 314:114648.
Score: 0.030
-
Shindul-Rothschild J, Rothschild AJ. Benzodiazepine response. Am J Nurs. 2001 Nov; 101(11):13-4.
Score: 0.029
-
Flint AJ, Rothschild AJ, Whyte EM, Alexopoulos GS, Mulsant BH, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Meyers BS. Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study. Am J Geriatr Psychiatry. 2021 07; 29(7):645-654.
Score: 0.027
-
Neufeld NH, Kaczkurkin AN, Sotiras A, Mulsant BH, Dickie EW, Flint AJ, Meyers BS, Alexopoulos GS, Rothschild AJ, Whyte EM, Mah L, Nierenberg J, Hoptman MJ, Davatzikos C, Satterthwaite TD, Voineskos AN. Structural brain networks in remitted psychotic depression. Neuropsychopharmacology. 2020 06; 45(7):1223-1231.
Score: 0.026
-
Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, Moore CM, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997 Apr 15; 41(8):837-43.
Score: 0.021